Sutro Biopharma, Inc. Quarterly report pursuant to Section 13 or 15(d)

Equity Incentive Plans, Equity Inducement Plans, Employee Stock Purchase Plan and Stock-Based Compensation (Tables)

6 Months Ended

Jun. 30, 2023

The following table summarizes option activity under the Company’s 2004 Plan, 2018 Plan and 2021 Plan:


	Shares			Weighted- Average Exercise Price
Stock options outstanding at December 31, 2022		7,310,611		$	12.68
Granted		1,368,000			5.66
Exercised		(53,060	)		5.92
Canceled and forfeited		(273,892	)		11.24
Stock options outstanding at June 30, 2023		8,351,659			11.62
Stock options exercisable at June 30, 2023		5,735,042		$	12.83

A summary of the status and activity of non-vested RSUs during the six months ended June 30, 2023 is as follows:


	Number of shares			Weighted Average Grant-Date Fair Value
Non-vested December 31, 2022		3,958,478		$	11.70
Granted		2,305,225			5.80
Vested and released		(896,269	)		12.52
Canceled and forfeited		(155,260	)		10.72
Non-vested June 30, 2023		5,212,174		$	8.98

Total stock-based compensation expense recognized was as follows:


	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2023		2022		2023		2022
	(in thousands)				(in thousands)
Research and development expense:	$	3,127	$	2,271	$	5,948	$	4,884
General and administrative expense:		3,534		4,425		6,734		8,786
Total	$	6,661	$	6,696	$	12,682	$	13,670